SWSandra M. Wells

Sandra M. Wells

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandra M. Wells has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Andrij Holian

    Department of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, Missoula, MT 59812, USA

    3 shared publications
  • Mary C. Buford

    Center for Environmental Health Sciences, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana

    3 shared publications
  • Jason Weigel

    Department of Environmental, Agricultural, and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska

    2 shared publications
  • Andrew B. Nevin

    Department of Environmental, Agricultural and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska; and 2Center for Environmental Health Sciences, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana

    1 shared publication
  • Christopher T. Migliaccio

    Center for Environmental Health Sciences, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana

    1 shared publication
  • Elizabeth B. Klein

    Department of Environmental, Agricultural, and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska

    1 shared publication

Latest Publications

  • Cigarette Smoke Suppresses PPAR-γ Expression and Activation In Murine Pulmonary Epithelial Cells

    by Sandra M. Wells, Jason Weigel, Fengxia Xiao, Elizabeth B. Klein

    Peroxisome proliferator–activated receptors (PPARs) are members of the nuclear hormone receptor superfamily and have antiinflammatory and immunomodulatory properties. PPAR-γ is expressed in many lung cell types, including epithelial cells and fibroblasts. Studies using PPAR-γ agonists have revealed that this isoform plays a role in both lung inflammation and pulmonary fibrosis, raising the possibility that PPAR-γ agonists may have potential in the treatment of lung diseases, including chronic obstructive pulmonary disease (COPD). Although it has been shown that cigarette smoke extract (CSE) reduces nuclear levels of activated PPAR-γ in a monocyte-macrophage cell line, the effects of CSE on PPAR-γ activation in pulmonary epithelial cells remains unexplored. We hypothesized that CSE exposure suppresses PPAR-γ expression and activation in pulmonary epithelial cells. Using a transcription factor enzyme-linked immunosorbent assay, we demonstrated that nuclear PPAR-γ activity was decreased by approximately 50% in a mouse lung epithelial cell line (LA-4) compared with controls following 3 hours of 10% CSE exposure. By 6 hours after CSE exposure, PPAR-γ mRNA expression, as measured by quantitative PCR, was also significantly decreased. Addition of the PPAR-γ agonist pioglitazone (10 μM) attenuated CSE-induced NF-κB activation linking PPAR-γ suppression to CSE-mediated inflammation. These findings indicate that suppression of PPAR-γ following cigarette smoke exposure may contribute to the pathogenesis of COPD in the lungs of smokers.

  • Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma

    by Elizabeth Klein, Jason Weigel, Mary C. Buford, Andrij Holian, Sandra M. Wells

    Nitric oxide (NO), formed by nitric oxide synthase (NOS), is an important mediator of lung inflammation in allergic asthma. Asymmetric dimethylarginine (ADMA), a competitive endogenous inhibitor of NOS, is metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). Elevated ADMA has been shown to affect lung function in mice, and by inhibiting NOS it alters NO and reactive oxygen species production in mouse lung epithelial cells. However, the effects of altered ADMA levels during lung inflammation have not been explored. A model of allergen-induced airway inflammation was utilized in combination with the modulation of endogenous circulating ADMA levels in mice. Airway inflammation was assessed by quantifying inflammatory cell infiltrates in lung lavage and by histology. Lung DDAH expression was assessed by quantitative PCR and immunohistochemistry. Nitrite levels were determined in lung lavage fluid as a measure of NO production. iNOS expression was determined by immunohistochemistry, immunofluorescence, Western blot, and quantitative PCR. NF-κB binding activity was assessed by a transcription factor binding assay. Allergen-induced lung inflammation was potentiated in mice with elevated circulating ADMA and was reduced in mice overexpressing DDAH. Elevated ADMA reduced nitrite levels in lung lavage fluid in both allergen-challenged and control animals. ADMA increased iNOS expression in airway epithelial cells in vivo following allergen challenge and in vitro in stimulated mouse lung epithelial cells. ADMA also increased NF-κB binding activity in airway epithelial cells in vitro. These data support that ADMA may play a role in inflammatory airway diseases such as asthma through modulation of iNOS expression in lung epithelial cells.


  • Role of the Serotonergic System in Reduced Pulmonary Function after Exposure to Methamphetamine

    by Sandra M. Wells, Mary C. Buford, Virginia M. Porter, Heather L. Brunell, Melisa Bunderson-Schelvan, Andrew B. Nevin, Fernando Cardozo-Pelaez, Andrij Holian

    Although use of methamphetamine (MA) by smoking is the fastest growing method of administration, very limited data are available describing the effects of smoked MA. Using a murine inhalation exposure system, we explored the pulmonary effects of low-dose acute inhalation exposure to MA vapor (smoke). Inhalation of MA vapor resulted in transiently reduced pulmonary function, as measured by transpulmonary resistance, dynamic compliance, and whole-body plethysmography compared with unexposed control animals. These changes were associated with an approximately 34% reduction in serotonin (5-hydroxytryptamine [5-HT]) metabolism/inactivation to 5-hydroxyindolacetic acid, and a nearly 40% reduction in monoamine oxidase (MAO)-A activity in the lung. Pretreatment of mice with a selective 5-HT reuptake inhibitor completely ablated the MA-induced changes in pulmonary function, confirming a key role for the 5-HT transporter (serotonin transporter [SERT]) and the serotonergic system in this effect. Immunofluorescent staining of mouse lung tissue confirmed high expression of SERT in airway epithelial cells. Using mouse airway epithelial cell line, LA-4, and purified human MAO-A, it was demonstrated that MA impedes 5-HT metabolism through direct inhibition of MAO-A activity in vitro. Together, these data demonstrate that low-dose exposure to MA results in reduced pulmonary function mediated via SERT and subsequent perturbation of 5-HT metabolism in the lung. This supports a role for the serotonergic system in MA-mediated pulmonary effects.


  • Elevated Asymmetric Dimethylarginine Alters Lung Function and Induces Collagen Deposition in Mice

    by Sandra M. Wells, Mary C. Buford, Christopher T. Migliaccio, Andrij Holian

    Increasing evidence suggests that lung mechanics and structure are maintained in part by an intimate balance between the L-arginine–metabolizing enzymes nitric oxide synthase (NOS) and arginase. Asymmetric dimethylarginine (ADMA) is a competitive endogenous inhibitor of NOS. The role of ADMA in the regulation of NOS and arginase in the airways has not yet been explored. Our objective was to investigate the role of ADMA in lung physiology. A murine model of continuous subcutaneous ADMA infusion via osmotic minipump was used for assessment of elevated ADMA in vivo, and primary lung fibroblasts were used for in vitro assessments. Two weeks after minipump placement, animals were anesthetized and mechanically ventilated, and lung mechanical responses were evaluated. Lungs were assessed histologically and biochemically for collagen content, arginase activity, and arginase protein levels. Lung lavage fluid was assessed for cellularity, nitrite, urea, and cytokine concentrations. ADMA infusion resulted in significantly enhanced lung resistance and decreased dynamic compliance in response to methacholine. These physiologic changes were associated with significantly increased lung collagen content in the absence of inflammation. Significant decreases in lung fluid nitrite were accompanied by elevated lung fluid urea and arginase activity in lung homogenates. These changes were reversed in mice 4 weeks after completion of ADMA administration. In addition, treatment of primary mouse lung fibroblasts with ADMA stimulated arginase activity and collagen formation in vitro. These data support the idea that ADMA may play a role in airway diseases, including asthma and pulmonary fibrosis, through NOS inhibition and enhancement of arginase activity.